New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
19:03 EDTTKMR, MONTekmira receives $1.5M milestone payment from Monsanto
Tekmira Pharmaceuticals (TKMR) announced that it has received a $1.5M milestone payment from Monsanto (MON) following completion of specified program developments. The development milestone is part of the research program under the option agreement Tekmira signed with the agriculture company, which was announced on January 13. The option agreement relates to Tekmira's proprietary delivery technology and intellectual property for use in agricultural applications. The potential value of the transaction could reach up to $86.2M, following the successful completion of all program milestones.
News For TKMR;MON From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 13, 2014
07:11 EDTTKMRTekmira volatility elevated, Texas health-care worker tests positive for Ebola
Subscribe for More Information
October 12, 2014
19:26 EDTTKMRPatient being evaluated at Boston hospital for possible Ebola, Boston Globe says
Health officials say that a man that recently traveled to Liberia is being assessed at Beth Israel Deaconess hospital in Boston for the Ebola virus, the Boston Globe says. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
19:12 EDTTKMRCDC confirms Texas healthcare worker positive for Ebola
Subscribe for More Information
17:20 EDTMONGE, Splunk, Cisco, others could benefit from Internet of Things, Barron's says
Subscribe for More Information
14:18 EDTTKMRNY's JFK Airport begins Ebola screenings, WSJ says
Subscribe for More Information
12:48 EDTTKMRTexas health-care worker tests positive for Ebola, WSJ says
Subscribe for More Information
October 10, 2014
12:05 EDTMONUSDA raises U.S. corn production estimate to 14.475B
Subscribe for More Information
10:54 EDTTKMRMapp looking to up production of experimental Ebola treatment, WSJ says
Mapp Biopharmaceutical is aiming to broaden the manufacturing of its experimental Ebola treatment, ZMapp, according to The Wall Street Journal, citing comments from the company. Mapp said that the treatment was given to a few infected individuals prior to supplies running out two months ago. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
October 9, 2014
14:55 EDTTKMRHospital says deputy showing no signs of Ebola, AP reports
Subscribe for More Information
14:24 EDTTKMRCDC head compares Ebola to AIDS, Washington Post says
Subscribe for More Information
14:13 EDTTKMRFirst Ebola vaccine trial in West Africa started, NBC News reports
Subscribe for More Information
12:06 EDTTKMRLakeland Industries continues surge amid Ebola fears
Subscribe for More Information
05:50 EDTTKMRStocks with implied volatility movement; ARWR TKMR
Stocks with implied volatility movement; Arrowhead (ARWR) 158, Tekmira (TKMR) 130 according to iVolatility.
October 8, 2014
11:59 EDTTKMRTekmira volatility increases after Ebola patient dies
Subscribe for More Information
11:22 EDTTKMRChimerix falls after Ebola patient taking experimental drug dies
Shares of Chimerix (CMRX) are moving lower after the Texas Health Presbyterian Hospital Dallas announced that Thomas Eric Duncan succumbed to Ebola. Duncan was being treated with Chimerix's experimental drug Brincidofovir. Shares of Chimerix dropped 9% following the news to $30.19. Other makers of experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT) and BioCryst (BCRX).
08:29 EDTMONMonsanto targets at least double ongoing EPS by FY19
Subscribe for More Information
08:08 EDTMONMonsanto sees Q1 earnings roughly half last year, FY15 growth concentrated in Q3
Monsanto said, "As its business has expanded globally over the past several years, the company has seen its earnings flow evolve between quarters. This trend continues in FY15 as the company anticipates an overall shift in its full-year earnings pattern, as several structural factors result in a full-year earnings flow with a smaller first quarter and a concentration of growth in the third quarter. With macro conditions resulting in lower planted acres for key regions in both corn and cotton in the quarter, combined with a timing shift as the company moves more of its Agricultural Productivity business to branded-product sales, Monsanto expects its first quarter will be roughly half of the total earnings from the first quarter of 2014. Beyond the first quarter, the biggest first half timing effect relates to the evolution in its Channel seed brand business model that is expected to shift business timing from the first and second quarters to the third quarter. The company expects second quarter earnings to be relatively flat year-over-year with a significant uptick in third quarter earnings reflecting the timing shifts and business growth in its largest markets. The earnings flow is punctuated by a fourth quarter that is expected to be break-even to positive year-over-year on an absolute basis."
08:06 EDTMONMonsanto reports Q4 Seeds and Genomics sales $1.376B
Reports Q4 Agricultural Productivity sales $1.254B. Hugh Grant, chairman and CEO for Monsanto, said, “In an industry that’s particularly near-term focused right now, there are few companies as well positioned to deliver strong growth today while significantly increasing investments to enable the continued delivery of a broad range of innovative solutions for tomorrow.”
08:04 EDTMONMonsanto sees FY15 EPS $5.75-$6.00, consensus $6.03
Subscribe for More Information
08:02 EDTMONMonsanto reports Q4 ongoing EPS (27c), consensus (24c)
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use